206 related articles for article (PubMed ID: 15205669)
21. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
22. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
24. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
[TBL] [Abstract][Full Text] [Related]
27. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
28. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
29. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.
Inamoto Y; Nishida T; Suzuki R; Miyamura K; Sao H; Iida H; Naoe T; Maruyama F; Hirabayashi N; Hamaguchi M; Iseki T; Kami M; Yano K; Takeyama H; Morishita Y; Morishima Y; Kodera Y
Bone Marrow Transplant; 2007 Jan; 39(1):25-30. PubMed ID: 17115063
[TBL] [Abstract][Full Text] [Related]
30. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
Majhail NS; Parks K; Defor TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
[TBL] [Abstract][Full Text] [Related]
31. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
[TBL] [Abstract][Full Text] [Related]
32. Acute renal failure after nonmyeloablative stem cell transplantation in adults.
Kersting S; Dorp SV; Theobald M; Verdonck LF
Biol Blood Marrow Transplant; 2008 Jan; 14(1):125-31. PubMed ID: 18158969
[TBL] [Abstract][Full Text] [Related]
33. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
Min CK; Kim SY; Lee MJ; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Cho CS
Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
36. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.
Massenkeil G; Nagy M; Neuburger S; Tamm I; Lutz C; le Coutre P; Rosen O; Wernecke KD; Dörken B; Arnold R
Bone Marrow Transplant; 2005 Oct; 36(8):683-9. PubMed ID: 16113673
[TBL] [Abstract][Full Text] [Related]
37. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy.
Worel N; Greinix HT; Leitner G; Mitterbauer M; Rabitsch W; Rosenmayr A; Höcker P; Kalhs P
Transfus Apher Sci; 2007 Jun; 36(3):297-304. PubMed ID: 17569587
[TBL] [Abstract][Full Text] [Related]
38. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
39. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
[TBL] [Abstract][Full Text] [Related]
40. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
